US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 1.060
- 0.0000.00%
Close Apr 26 16:00 ET
- 1.090
- +0.030+2.83%
Post 18:54 ET
123.45MMarket Cap-848P/E (TTM)
1.080High1.020Low660.74KVolume1.050Open1.060Pre Close691.05KTurnover0.62%Turnover RatioLossP/E (Static)116.47MShares3.86552wk High-0.91P/B112.96MFloat Cap0.61752wk Low--Dividend TTM106.57MShs Float49.005Historical High--Div YieldTTM5.66%Amplitude0.617Historical Low1.045Avg Price1Lot Size
Karyopharm Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 38.00%-92.72M | 30.76%-18.59M | -4.09%-29.53M | 26.88%-25.7M | 68.06%-18.91M | -39.62%-149.55M | -205.37%-26.84M | -18.43%-28.37M | 36.96%-35.14M | -11.93%-59.2M |
| Net income from continuing operations | 13.43%-143.1M | -8.65%-41.84M | 5.00%-34.51M | 33.49%-32.63M | 17.57%-34.13M | -33.20%-165.29M | -199.45%-38.51M | 29.89%-36.32M | 8.44%-49.06M | 27.89%-41.4M |
| Depreciation and amortization | -14.65%530K | -31.86%77K | -56.04%80K | -44.30%83K | 63.84%290K | -21.29%621K | -18.71%113K | -2.15%182K | -34.93%149K | -24.68%177K |
| Other non cash items | 54.43%820K | 423.53%220K | 0.99%205K | -5.00%190K | 4.59%205K | -93.39%531K | -409.09%-68K | -97.25%203K | -53.05%200K | 2.62%196K |
| Change In working capital | 257.16%31.42M | 218.06%18.79M | -48.31%549K | 214.63%1.61M | 140.93%10.46M | 13.80%-19.99M | 128.11%5.91M | -91.56%1.06M | 86.92%-1.41M | -540.24%-25.55M |
| -Change in receivables | 495.83%20.12M | 8,219.26%10.96M | -42.25%-5.64M | 92.99%2.92M | 576.39%11.89M | 47.13%-5.08M | 96.40%-135K | -358.61%-3.97M | 3,538.64%1.51M | 49.72%-2.5M |
| -Change in inventory | 1,100.85%1.18M | 148.00%62K | 172.79%567K | -61.63%155K | 71.12%397K | 91.93%-118K | 132.47%25K | -743.80%-779K | 142.35%404K | 142.03%232K |
| -Change in prepaid assets | 215.43%6.67M | -51.62%1.06M | -43.51%3.89M | -74.73%187K | 109.85%1.54M | 76.65%-5.78M | 110.08%2.2M | 147.06%6.88M | 113.02%740K | -17,428.09%-15.6M |
| -Change in payables and accrued expense | 151.95%4.35M | 71.94%6.96M | 309.41%1.96M | 63.70%-1.43M | 58.38%-3.14M | -163.78%-8.37M | -8.11%4.05M | -108.77%-935K | 1.03%-3.93M | -473.39%-7.55M |
| -Change in other current assets | 16.99%1.96M | 17.38%520K | 17.37%500K | 16.79%480K | 16.37%462K | 15.73%1.68M | 15.67%443K | 15.76%426K | 15.77%411K | 15.74%397K |
| -Change in other current liabilities | -24.01%-2.87M | -15.36%-766K | -27.39%-721K | -27.82%-703K | -27.24%-682K | -20.81%-2.32M | -29.94%-664K | -17.43%-566K | -17.52%-550K | -17.54%-536K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 38.00%-92.72M | 30.76%-18.59M | -4.09%-29.53M | 26.88%-25.7M | 68.06%-18.91M | -39.62%-149.55M | -205.37%-26.84M | -18.43%-28.37M | 36.96%-35.14M | -11.93%-59.2M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 107.62%7.94M | 141.11%26.84M | -165.84%-7.69M | 157.85%21.17M | -130.77%-32.39M | -173.50%-104.26M | -312.21%-65.3M | -45.52%11.67M | -178.77%-36.6M | -132.50%-14.04M |
| Net PPE purchase and sale | --0 | --0 | --0 | --0 | --0 | 44.34%-118K | --0 | -680.00%-39K | --0 | ---79K |
| Net intangibles purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | 107.62%7.94M | 141.11%26.84M | -165.62%-7.69M | 157.85%21.17M | -132.07%-32.39M | -170.58%-104.14M | -314.25%-65.3M | -57.30%11.71M | -178.77%-36.6M | -132.32%-13.96M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 107.62%7.94M | 141.11%26.84M | -165.84%-7.69M | 157.85%21.17M | -130.77%-32.39M | -173.50%-104.26M | -312.21%-65.3M | -45.52%11.67M | -178.77%-36.6M | -132.50%-14.04M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -99.42%1.12M | -99.83%264K | 0 | -34.50%860K | 0 | 163.06%193.74M | 17,293.19%155.84M | 36,143.75%5.8M | -97.88%1.31M | 188.34%30.78M |
| Net common stock issuance | --0 | --0 | --0 | --0 | --0 | 1,816.20%189.76M | --154.68M | --5.79M | ---22K | 196.03%29.32M |
| Proceeds from stock option exercised by employees | -71.74%1.12M | -77.32%264K | --0 | -35.58%860K | --0 | 6.19%3.98M | 29.91%1.16M | -31.25%11K | -35.19%1.34M | 89.78%1.47M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -99.42%1.12M | -99.83%264K | --0 | -34.50%860K | --0 | 163.06%193.74M | 17,293.19%155.84M | 36,143.75%5.8M | -97.88%1.31M | 188.34%30.78M |
| Net cash flow | ||||||||||
| Beginning cash position | -30.67%136.89M | -38.98%44.58M | -2.59%81.85M | -44.78%85.54M | -30.67%136.89M | 121.55%197.45M | -47.98%73.06M | -41.12%84.03M | 72.11%154.91M | 121.55%197.45M |
| Current changes in cash | -39.26%-83.66M | -86.62%8.52M | -241.48%-37.22M | 94.79%-3.67M | -20.85%-51.3M | -155.43%-60.07M | 11.48%63.7M | -333.66%-10.9M | -233.46%-70.43M | -4,458.21%-42.45M |
| Effect of exchange rate changes | 93.03%-34K | -29.37%89K | 25.71%-52K | 94.27%-26K | 50.00%-45K | -916.67%-488K | 193.33%126K | -128.93%-70K | -609.38%-454K | 1.10%-90K |
| End cash Position | -61.14%53.19M | -61.14%53.19M | -38.98%44.58M | -2.59%81.85M | -44.78%85.54M | -30.67%136.89M | -30.67%136.89M | -47.98%73.06M | -41.12%84.03M | 72.11%154.91M |
| Free cash flow | 38.05%-92.72M | 30.76%-18.59M | -3.95%-29.53M | 26.88%-25.7M | 68.10%-18.91M | -32.66%-149.67M | -204.17%-26.84M | 5.18%-28.41M | 36.96%-35.14M | -12.08%-59.28M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg